Pular para o conteúdo principal
Ranking Invest

CLDX - Celldex Therapeutics, Inc.

Segmento: HealthcareCelldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Análise Ranking Invest

Valuation estimado
$ 16.50 Mi
Valor de Mercado
$ 2.90 Bi
Sobrepreço (AV)+17460.8%
IVR
0.01A companhia vale 0,01 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
-0.24O valuation alternativo equivale a -24% do valor de mercado da companhia.
MLL
-0.24O lucro líquido dos controladores em 16 trimestres equivale a -24% do valor de mercado.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 714.56 Mi

Dívida Líquida

-$ 47.45 Mi

L4T

-$ 300.55 Mi

MM4T

-214667.80%

Indicadores Básicos

ROE

-42.06%

Índices de Previsibilidade

Receita Líquida

G0.80

Lucro

A0.13

Margem

E1.14

Índices de Tendência

Receita Líquida

E-3.97

Lucro

G-11.20

Margem

F-5.41

Índices de Endividamento

DIV/PAT

-0.07

DIV/L4T

0.16

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.